Arcellx

Arcellx Net Tangible Assets

Delisted

The Net Tangible Assets of Arcellx (ACLX) as of Nov 21, 2026 is 402.35 M USD. In the previous year, Net Tangible Assets was 454.79 M USD — a change of -11.53% (lower).

Net Tangible Assets

402.35 MUSD

YoY

-11.53%

Last updated:

Net Tangible Assets of Arcellx is 2025 402.35 M USD. Net Tangible Assets of Arcellx was 2024 454.79 M USD. It decreases by -11.53% lower compared to the previous year.

The Arcellx Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
13.96 M USD
Jan 1, 2019
-32.74 M USD
Jan 1, 2020
50.54 M USD
Jan 1, 2021
-121.52 M USD
Jan 1, 2022
204.95 M USD
Jan 1, 2023
485.38 M USD
Jan 1, 2024
454.79 M USD
Jan 1, 2025
402.35 M USD
The Arcellx Net Tangible Assets history
YEARNet Tangible AssetsYoY
402.35 MUSD-11.53%
454.79 MUSD-6.30%
485.38 MUSD+136.82%
204.95 MUSD-268.67%
-121.52 MUSD-340.43%
50.54 MUSD-254.38%
-32.74 MUSD-334.53%
13.96 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Net Tangible Assets of Arcellx is 402.35 M USD in 2025.

Net Tangible Assets of Arcellx changed from 454.79 M USD to 402.35 M USD, representing a -11.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Arcellx since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Arcellx

All Key Metrics — Arcellx